Fiji has declared a national health emergency over HIV, a move that sounds decisive until you learn that the government's own HIV response unit had been requesting it since June 2024, that advocates flagged children sharing needles as early as 2019, and that the legal framework still criminalizes distributing the clean syringes sitting in boxes in a Suva warehouse. The emergency is real. The response architecture is not yet built. The numbers are staggering for a nation of 930,000. An estimated 9,100 people are living with HIV — one in 60 adults. New diagnoses hit 2,016 in 2025, a 27% year-on-year increase and a 12-fold rise since 2010. Only 39% of those infected know their status. Among pregnant women, prevalence is now 2 in 100. The epidemic is young: new diagnoses peak in the 15-34 age bracket, and primary school-age children are among those injecting methamphetamine with shared needles. The transmission pathway is brutally clear. More than 42% of new 2025 cases trace to contaminated injection equipment. Fiji sits on a Pacific drug transit corridor feeding Australian and New Zealand methamphetamine markets. When Covid closed borders, trapped supply turned inward, and domestic meth use exploded. The HIV epidemic is, in structural terms, a second-order consequence of the drug trade, and any response that treats the virus without treating the needle supply chain is treating symptoms. The legal bottleneck is almost farcical. Distributing syringes is technically aiding and abetting drug use under current law, despite UNAids evidence that needle exchanges do not increase drug use. Dr. Jason Mitchell, who leads Fiji's HIV response, says a change to the HIV Act should pass within two weeks. Meanwhile, the syringes sit in a warehouse. Six years after advocates first raised the alarm about children sharing needles, the legislative fix is still pending. International money is arriving but modest relative to the scale. Australia committed A$48m for Pacific HIV/Aids efforts; New Zealand pledged NZ$4.2m specifically for Fiji. Mitchell estimates the emergency response costs an additional $23m FJD (US$10.2m) annually. The introduction of injectable PrEP — one shot every six months — is described as a potential game-changer, particularly for women unable to negotiate condom use with partners. But rollout timelines remain vague. The social costs are already compounding. Stigma is driving people away from testing. Cyberbullying targets the queer community and women. Rural areas lag badly on treatment access. Burnout among health workers who have been operating in crisis mode for 21 months is a stated concern. Mitchell projects five to ten years to bring the epidemic under control, with case numbers expected to rise before they fall. The structural lesson is familiar: a preventable crisis allowed to metastasize through legal inertia, stigma, and institutional reluctance to act on early warnings. Advocates identified the needle-sharing problem among children in 2019. The government declared an emergency in February 2025 but waited months to scale up. The pattern — clear evidence, delayed action, emergency declaration after the curve has steepened — is extractive in a specific sense: the cost of institutional slowness is paid entirely by the most vulnerable, in this case teenagers and pregnant women in a small Pacific nation.
